Antigen-Capturing Nanoparticles for Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy methods have low response rates due to limited antigen presentation and tumor heterogeneity, as they often focus on specific tumor antigens rather than a wide variety of tumor-derived proteins, which are difficult to target effectively.
Innovation Solution
Development of antigen-capturing nanoparticles (AC-NPs) that bind to tumor-derived proteins and antigens released after radiotherapy, enhancing their presentation to immune cells, particularly dendritic cells, to stimulate a robust immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cancer immunotherapy methods are used, then the treatment approach is simple, but the response rate is low
Solution Approach 1:
The patent introduces antigen-capturing nanoparticles as an intermediary between radiotherapy and the immune system. These nanoparticles capture tumor antigens released during radiotherapy and deliver them to dendritic cells, serving as a bridge that enhances immune recognition without requiring complex multi-component systems
Solution Approach 2:
The nanoparticles are pre-engineered with antigen-capturing capabilities and targeting moieties before administration. This preliminary preparation allows them to immediately capture antigens upon radiotherapy-induced tumor cell lysis, eliminating the need for complex in vivo antigen processing steps
2Reliability
If specific tumor antigens are targeted, then the treatment is focused, but the effectiveness is limited due to tumor heterogeneity
Solution Approach 1:
The nanoparticles are designed with universal antigen-capturing surfaces that can bind multiple different tumor antigens simultaneously. The surface chemistry allows non-specific protein adsorption, enabling the same nanoparticle formulation to capture diverse antigens from heterogeneous tumors without requiring antigen-specific customization
Solution Approach 2:
The patent utilizes changes in surface charge and hydrophobicity parameters of the nanoparticle surface to optimize antigen capture. By controlling these physical-chemical parameters, the nanoparticles can effectively bind a broad spectrum of tumor antigens with varying properties, addressing tumor heterogeneity
3Reliability
If tumor cell lysates are used, then the antigen source is available, but the antigen presentation is insufficient
Solution Approach 1:
The patent replaces the natural, inefficient mechanical process of antigen presentation with a engineered nanoparticle-mediated delivery system. The nanoparticles provide a controlled interface between tumor antigens and dendritic cells, substituting the unreliable natural lysate presentation with a designed delivery mechanism
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The AC-NPs significantly enhance cancer immunotherapy by increasing the activation of cytotoxic and helper T cells, delaying tumor growth, and improving survival rates, including in cases of metastatic disease, by presenting a wide range of tumor antigens to the immune system.
Implementation Method 1
antigen-capturing nanoparticles (AC-NPs) that bind to tumor-derived proteins and antigens released after radiotherapy
Data Source
AI summary
Disclosed herein are antigen-capturing nanoparticles. Specifically, the subject matter contained herein pertains to novel nanoparticles that can capture a multitude of tumor antigens that are released from tumor cells. Also, provided herein are methods for preparing the antigen-capturing nanoparticles and methods for the treatment of disease in a subject comprising administering the antigen-capturing nanoparticles.